Afatinib，10MG，SML3109-10MG，Sigma

Biochem/physiol Actions

Afatinib (BIBW2992) is an orally active, irreversible, potent and selective EGFR/HER2 (ErbB2) dual inhibitor (EGFR IC50 = 0.5 nM (Wt), 0.4 nM (L858R), 10 nM (L858R/T790M); HER2 IC50 = 14 nM) that covalently targets EGFR Cys773 and HER2 Cys805 residues. BIBW2992 suppresses 100 ng/mL EGF-induced EGFR/HER2 tyrosin phosphorylation (IC50 = 13-71 nM; A431, NIH-3T3-HER2, BT-474, NCI-N87), inhibits cancer cells survival in cultures and induces tumor regression in xenograft and transgenic lung cancer models in vivo (20 mg/kg/day p.o.).
Orally active, irreversible, potent and selective EGFR/HER2 (ErbB2) dual inhibitor with in vitro and in vivo anti-cancer efficacy.